Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Cell. Infect. Microbiol.

Sec. Virus and Host

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1627668

This article is part of the Research TopicStrategies of Virus PersistenceView all articles

Towards the Elimination of Infectious HPV: Exploiting CRISPR/Cas Innovations

Provisionally accepted
Wei LiuWei Liu1Yingyan JiangYingyan Jiang2Cheng WangCheng Wang1Min WangMin Wang3Wei ZhangWei Zhang1Haiying RenHaiying Ren4Shiyan XuShiyan Xu1Jinjing QinJinjing Qin1Pan LiuPan Liu1Lianhai JinLianhai Jin1*Donghai ZhaoDonghai Zhao1*
  • 1Jilin Medical University, Jilin, China
  • 2Affiliated hospital of Jilin medical university, Jilin, China
  • 3The Second Hospital of Jilin University, Changchun, China
  • 4Jilin Sixth People's Hospital, Jilin, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

HPV has been conclusively associated with various human malignancies, making the development of prevention and treatment strategies for HPV-induced diseases a high priority. Currently, primary prevention methods include HPV immunization and routine screening, which significantly reduce the risk of HPV transmission. However, for patients diagnosed with invasive, advanced, or recurrent malignancies, non-virus-specific therapies frequently lead to drug resistance and adverse effects, resulting in minimal improvement in treatment efficacy for numerous patients. Viral genome-targeting therapy is emerging as a promising avenue for the future management of HPV infections. With the rapid advancement of genetic modification technologies, the CRISPR/Cas system has demonstrated significant potential in treating viral infections. Its ability to selectively target and edit viral genomes for elimination positions it as a highly effective approach for combating HPV. This review will explore the functions and applications of the CRISPR/Cas system as an innovative therapy for HPV. We will illustrate the prospective efficacy of CRISPR/Cas as a groundbreaking and promising cure for HPV infections, while also addressing the opportunities and challenges associated with this novel approach.KEY WORDS：HPV，CRISPR/Cas，gene editing，viral genome targeting therapy，HPV-associated diseases

Keywords: HPV, CRiSPR/Cas, gene editing, viral genome targeting therapy, HPV-associated diseases

Received: 13 May 2025; Accepted: 15 Jul 2025.

Copyright: © 2025 Liu, Jiang, Wang, Wang, Zhang, Ren, Xu, Qin, Liu, Jin and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Lianhai Jin, Jilin Medical University, Jilin, China
Donghai Zhao, Jilin Medical University, Jilin, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material